Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Notes Payables: 2011-2020

Historic Notes Payables for Adma Biologics (ADMA) over the last 5 years, with Dec 2020 value amounting to $100.0 million.

  • Adma Biologics' Notes Payables was N/A to $100.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $100.0 million, marking a year-over-year change of. This contributed to the annual value of $100.0 million for FY2020, which is N/A change from last year.
  • According to the latest figures from FY2020, Adma Biologics' Notes Payables is $100.0 million, which was up 233.33% from $30.0 million recorded in FY2018.
  • Adma Biologics' Notes Payables' 5-year high stood at $100.0 million during FY2020, with a 5-year trough of $20.0 million in FY2016.
  • Its 2-year average for Notes Payables is $65.0 million, with a median of $65.0 million in 2018.
  • Data for Adma Biologics' Notes Payables shows a peak YoY soared of 50.00% (in 2017) over the last 5 years.
  • Yearly analysis of 4 years shows Adma Biologics' Notes Payables stood at $20.0 million in 2016, then spiked by 50.00% to $30.0 million in 2017, then remained steady at $30.0 million in 2018, then reached $100.0 million in 2020.